<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="0418a37f-ea81-480e-8696-8ad0229679af"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use TRODELVY safely and effectively. See full prescribing information for TRODELVY <br/>
      <br/> TRODELVY<sup>®</sup> (sacituzumab govitecan-hziy) for injection, for intravenous use <br/>Initial U.S. Approval: 2020</title>
   <effectiveTime value="20250331"/>
   <setId root="57a597d2-03f0-472e-b148-016d7169169d"/>
   <versionNumber value="17"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="185049848" root="1.3.6.1.4.1.519.1"/>
            <name>Gilead Sciences, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="1d4e824e-116c-455f-a90e-a4b86a01e54e"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250331"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="55135-132" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>TRODELVY</name>
                        <formCode code="C42973" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>SACITUZUMAB GOVITECAN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="180" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="M9BYU8XDQ6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SACITUZUMAB GOVITECAN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="M9BYU8XDQ6" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SACITUZUMAB GOVITECAN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2GNK67Q0C4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>2-(N-morpholino)ethanesulfonic acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B8WCK70T7I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>trehalose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polysorbate 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="55135-132-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20200423"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200422"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761115" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="96c99cc3-2e2b-45f1-ba26-7e26ecd366e8"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="emphasis">WARNING: NEUTROPENIA AND DIARRHEA</content>
               </title>
               <text>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">
                           <content styleCode="xmChange">TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm<sup>3</sup> or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>. Initiate anti-infective treatment in patient with febrile neutropenia without delay <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                           </content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="xmChange">TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content> If severe diarrhea occurs, withhold TRODELVY until resolved to</content>
                        </content> ≤ <content styleCode="bold">Grade 1 and reduce subsequent doses <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>].</content>
                        </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: NEUTROPENIA AND DIARRHEA</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">See full prescribing information for complete boxed warning</content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm<sup>3</sup> or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia. Initiate anti-infective treatment in patients with febrile neutropenia without delay. (<linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses. (<linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="fec1bf16-5b10-4039-8083-becdb3b6844b"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="75%" align="left" valign="top"/>
                           <col width="25%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <linkHtml href="#BOX">Boxed Warning</linkHtml>
                                 </td>
                                 <td>03/2025</td>
                              </tr>
                              <tr>
                                 <td>Indications and Usage, Locally Advanced or Metastatic Urothelial Cancer – Accelerated Approval (text removed) (1.2)</td>
                                 <td>11/2024</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S2.4">2.4</linkHtml>)</td>
                                 <td>03/2025</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<linkHtml href="#S5.1">5.1</linkHtml>)</td>
                                 <td>03/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="faf6267d-a44a-4878-9351-df9ff70a3684"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:</paragraph>
                        <paragraph>
                           <content styleCode="underline">Locally Advanced or Metastatic Breast Cancer</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. (<linkHtml href="#S1.1">1.1</linkHtml>, <linkHtml href="#S14.1">14.1</linkHtml>)</item>
                           <item>Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. (<linkHtml href="#S1.1">1.1</linkHtml>, <linkHtml href="#S14.2">14.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="ab07b2c4-da41-41aa-aa8a-44c83a915632"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1  Locally Advanced or Metastatic Breast Cancer</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.</item>
                           <item>TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="b21be8c7-6320-4d40-8b25-363b38a08e8c"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Do NOT substitute TRODELVY for or use with other drugs containing irinotecan or its active metabolite SN-38. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>For intravenous infusion only. Do not administer as an intravenous push or bolus.</item>
                           <item>The recommended dose is 10 mg/kg once weekly on Days 1 and 8 of continuous 21-day treatment cycles until disease progression or unacceptable toxicity. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>Premedication for prevention of infusion reactions and prevention of chemotherapy-induced nausea and vomiting is recommended. (<linkHtml href="#S2.2">2.2</linkHtml>) </item>
                           <item>Primary prophylaxis with G-CSF is recommended starting in the first cycle in all patients at increased risk of febrile neutropenia. (<linkHtml href="#S2.2">2.2</linkHtml>) </item>
                           <item>Monitor patients during the infusion and for at least 30 minutes after completion of infusion. Treatment interruption and/or dose reduction may be needed to manage adverse reactions. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>See Full Prescribing Information for preparation and administration instructions. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="3bbe430d-ef14-4f2f-a095-7cd07f8bb43f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Use Information </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Do NOT substitute TRODELVY for or use with other drugs containing irinotecan or its active metabolite SN-38.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="f4625174-a010-462b-b067-06f23a57fe13"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended dosage of TRODELVY is 10 mg/kg administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles. Continue treatment until disease progression or unacceptable toxicity. Do not administer TRODELVY at doses greater than 10 mg/kg.</paragraph>
                        <paragraph>Administer TRODELVY as an intravenous infusion only. Do not administer as an intravenous push or bolus.</paragraph>
                        <paragraph>First infusion: Administer infusion over 3 hours. Observe patients during the infusion and for at least 30 minutes following the initial dose, for signs or symptoms of infusion-related reactions <content styleCode="italics">[see <linkHtml href="#S5.3">Warning and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>Subsequent infusions: Administer infusion over 1 to 2 hours if prior infusions were tolerated. Observe patients during the infusion and for at least 30 minutes after infusion.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="7707546a-c514-4497-9976-fc3d9b8ffe06"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Premedication</content>
                              </paragraph>
                              <paragraph>Prior to each dose of TRODELVY, premedication for prevention of infusion reactions and prevention of chemotherapy-induced nausea and vomiting (CINV) is recommended.</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Premedicate with antipyretics, H1 and H2 blockers prior to infusion, and corticosteroids may be used for patients who had prior infusion reactions.</item>
                                 <item>Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK<sub>1</sub> receptor antagonist, as well as other drugs as indicated).</item>
                              </list>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="cf4ad783-dedc-42e9-89f9-8531845e4b6f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Prophylaxis for Neutropenia</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is recommended starting in the first cycle for all patients at increased risk of febrile neutropenia <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="3d74747b-f64f-4f09-9e3c-9d617716efc7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dose Modifications for Adverse Reactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Management of adverse reactions may require temporary interruption, dose reduction, or treatment discontinuation of TRODELVY as described in Tables 1 and 2. Do not re-escalate the TRODELVY dose after a dose reduction for adverse reactions has been made.</content>
                        </paragraph>
                        <table width="60%">
                           <caption>Table 1: Dosage Reduction Levels</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">
                                    <content styleCode="xmChange">Dose Level</content>
                                 </th>
                                 <th styleCode="Rrule">Dosage and Schedule</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="xmChange">Recommended starting dose</content>
                                 </td>
                                 <td styleCode="Rrule">10 mg/kg once weekly on Days 1 and 8 of 21-day treatment cycles</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="xmChange">First dose reduction</content>
                                 </td>
                                 <td styleCode="Rrule">	Reduce to 7.5 mg/kg</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="xmChange">Second dose reduction</content>
                                 </td>
                                 <td styleCode="Rrule">Reduce to 5 mg/kg</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="xmChange">Requirement for further dose reduction</content>
                                 </td>
                                 <td styleCode="Rrule">Permanently discontinue TRODELVY</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The recommended dosage modifications for adverse reactions are provided in Table 2.</paragraph>
                        <table width="90%">
                           <caption>Table 2: Dose Modifications for Adverse Reactions</caption>
                           <col width="20%" align="left" valign="top"/>
                           <col width="30%" align="left" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" align="center">
                                    <content styleCode="xmChange">Adverse reactions</content>
                                 </th>
                                 <th styleCode="Rrule" align="center">Severity</th>
                                 <th styleCode="Rrule" align="center">Dose Modification</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Neutropenia </content>
                                       <br/>
                                       <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                                    </content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Grade 3–4 neutropenia (Absolute Neutrophil Count [ANC] &lt;1000/mm<sup>3</sup>) or febrile neutropenia</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold TRODELVY until ANC ≥1500/mm<sup>3</sup> for Day 1 dose or ANC ≥1000/mm<sup>3</sup> for Day 8 Dose </item>
                                       <item>Administer G-CSF during treatment as clinically indicated.</item>
                                       <item>Reduce one dose level for each occurrence of febrile neutropenia or prolonged Grade 3–4 neutropenia, or discontinue according to Table 1.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Nausea/Vomiting/ Diarrhea </content>
                                       <br/>
                                       <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#S5.4">5.4)</linkHtml>]</content>
                                    </content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Grade 3–4 nausea, vomiting or diarrhea that is not controlled with antiemetics or anti-diarrheal agents</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold TRODELVY until resolved to ≤ Grade 1</item>
                                       <item>Reduce one dose level with each occurrence, or discontinue according to Table 1.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Infusion-Related Reaction</content>
                                       <br/>
                                       <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                                    </content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Grade 1–3 infusion-related reactions</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Slow infusion rate or interrupt the infusion </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Grade 4 infusion-related reactions</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Discontinue TRODELVY.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Other Toxicities</content>
                                    </content>
                                 </td>
                                 <td styleCode="Rrule">Other Grade 3–4 toxicities of any duration despite optimal medical management</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold TRODELVY until resolved to ≤ Grade 1</item>
                                       <item>Reduce one dose level with each occurrence or discontinue according to Table 1.</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="b96eeb9c-1c4a-451d-9ed7-45f28df57ad4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Preparation and Administration</title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="8c7f2c6e-93d1-489e-8d29-1605dc778576"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Reconstitution</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>TRODELVY is a hazardous drug.</item>
                                 <item>Follow applicable special handling and disposal procedures<sup>1</sup>.</item>
                                 <item>
                                    <content styleCode="xmChange">Calculate the required dose (mg) of TRODELVY based on the patient's current body weight <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</content>
                                 </item>
                                 <item>Using a sterile syringe, slowly inject 20 mL of 0.9% Sodium Chloride Injection, USP, into each 180 mg TRODELVY vial. Each vial contains overfill to compensate for liquid loss during preparation and after reconstitution, the total resulting volume delivers a <content styleCode="bold">concentration of 10 mg/mL</content>.</item>
                                 <item>Gently swirl vials and allow to dissolve for up to 15 minutes. Do not shake. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The solution should be free of visible particulates, clear and yellow. Do not use the reconstituted solution if it is cloudy or discolored.</item>
                                 <item>Use immediately to prepare a diluted TRODELVY infusion solution.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="774f1697-3e2a-4f97-a629-928b7de6f8e5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dilution</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Calculate the required amount of the reconstituted TRODELVY solution needed to obtain the appropriate dose according to the patient's body weight.</item>
                                 <item>Determine the final volume of the infusion solution to deliver the appropriate dose at a TRODELVY concentration range of 1.1 mg/mL to 3.4 mg/mL.</item>
                                 <item>Use 0.9% Sodium Chloride Injection, USP only since the stability of the reconstituted TRODELVY solution has not been determined with other infusion-based solutions. Use a polyvinyl chloride, polypropylene/polyethylene, polyolefin, or ethylene vinyl acetate infusion bag.</item>
                                 <item>Withdraw and discard the volume of 0.9% Sodium Chloride Injection, USP from the final infusion bag that is necessary to achieve the indicated TRODELVY concentration following the addition of the calculated amount of reconstituted TRODELVY solution.</item>
                                 <item>Withdraw the calculated amount of the reconstituted TRODELVY solution from the vial(s) using a syringe. Discard any unused portion remaining in the vial(s).</item>
                                 <item>To minimize foaming, slowly inject the calculated amount of reconstituted TRODELVY solution into the infusion bag. Do not shake the contents.</item>
                                 <item>If not used immediately, the infusion bag containing TRODELVY solution can be stored refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours protected from light. After refrigeration, administer diluted solution at room temperature up to 25°C (77°F) within 8 hours (including infusion time).</item>
                              </list>
                              <paragraph>Do Not Freeze or Shake.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="19ad9475-0e08-491e-8757-77a0e2f44899"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Administration</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Administer TRODELVY as an intravenous infusion. Protect infusion bag from light. The infusion bag should be covered during administration to the patient until dosing is complete. It is not necessary to cover the infusion tubing or to use light-protective tubing during the infusion.</item>
                                 <item>An infusion pump may be used.</item>
                                 <item>Do not mix TRODELVY, or administer as an infusion, with other medicinal products.</item>
                                 <item>Upon completion of the infusion, flush the intravenous line with 20 mL 0.9% Sodium Chloride Injection, USP.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="891a44cf-4535-48a7-8fa8-5a86032c42bf"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>For injection: 180 mg off-white to yellowish lyophilized powder in a single-dose vial.</paragraph>
               </text>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For injection: 180 mg lyophilized powder in single-dose vials for reconstitution. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="1f7a11de-0af2-4209-b7b6-cfe7717710ff"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>TRODELVY is contraindicated in patients who have experienced a severe hypersensitivity reaction to TRODELVY <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Severe hypersensitivity reaction to TRODELVY. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="bfd2d843-a852-4f58-ab52-b0fe6703a21a"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Hypersensitivity and Infusion-Related Reactions: Hypersensitivity reactions including severe anaphylactic reactions have been observed. Monitor patients for infusion-related reactions. Permanently discontinue TRODELVY if severe or life-threatening reactions occur. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>Nausea/Vomiting: Use antiemetic preventive treatment and withhold TRODELVY for patients with Grade 3 nausea or Grade 3–4 vomiting at the time of scheduled treatment. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                           <item>Patients with Reduced UGT1A1 Activity: Individuals who are homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia following initiation of TRODELVY treatment. (<linkHtml href="#S5.5">5.5</linkHtml>)</item>
                           <item>Embryo-Fetal Toxicity: TRODELVY can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. (<linkHtml href="#S5.6">5.6</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>, <linkHtml href="#S8.3">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="31f43e07-0b5c-472b-bfa4-a51a8b034af4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Neutropenia</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">TRODELVY can cause severe, life-threatening, or fatal neutropenia as early as the first cycle of treatment.  Neutropenia occurred in 64% of patients treated with TRODELVY. Grade 3–4 neutropenia occurred in 49% of patients. Febrile neutropenia occurred in 6% of patients. The median time to first onset of neutropenia (including febrile neutropenia) was 16 days (range: 1 to 435 days). Neutropenia occurred earlier in patients with reduced UGT1A1 activity <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>. Neutropenic colitis occurred in 1.4% of patients.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Primary prophylaxis with G-CSF is recommended starting in the first cycle of treatment in all patients at increased risk of febrile neutropenia, including older patients, patients with previous neutropenia, poor performance status, organ dysfunction, or multiple comorbidities.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Monitor absolute neutrophil count (ANC) during treatment. Withhold TRODELVY for ANC below 1500/mm<sup>3</sup> on Day 1 of any cycle or below 1000/mm<sup>3</sup> on Day 8 of any cycle. Withhold TRODELVY for neutropenic fever. Dose modifications may be required due to neutropenia. Treat neutropenia with G-CSF and administer prophylaxis in subsequent cycles as clinically indicated or indicated in Table 2 <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="3620dfdb-d8f4-40c1-8026-ab08d528f61c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Diarrhea</title>
                     <text>
                        <paragraph>TRODELVY can cause severe diarrhea. Diarrhea occurred in 64% of all patients treated with TRODELVY. Grade 3–4 diarrhea occurred in 11% of all patients treated with TRODELVY. One patient had intestinal perforation following diarrhea. Diarrhea that led to dehydration and subsequent acute kidney injury occurred in 0.7% of all patients.</paragraph>
                        <paragraph>Withhold TRODELVY for Grade 3–4 diarrhea at the time of scheduled treatment administration and resume when resolved to ≤ Grade 1 <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>At the onset of diarrhea, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g., fluid and electrolyte substitution) may also be employed as clinically indicated.</paragraph>
                        <paragraph>Patients who exhibit an excessive cholinergic response to treatment with TRODELVY (e.g., abdominal cramping, diarrhea, salivation, etc.) can receive appropriate premedication (e.g., atropine) for subsequent treatments.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="08988f24-316d-4430-993d-c697dcfe9a4d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hypersensitivity and Infusion-Related Reactions</title>
                     <text>
                        <paragraph>TRODELVY can cause serious hypersensitivity reactions including life-threatening anaphylactic reactions. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                        <paragraph>Hypersensitivity reactions within 24 hours of dosing occurred in 35% of patients treated with TRODELVY. Grade 3–4 hypersensitivity occurred in 2% of patients treated with TRODELVY. The incidence of hypersensitivity reactions leading to permanent discontinuation of TRODELVY was 0.2%. The incidence of anaphylactic reactions was 0.2%.</paragraph>
                        <paragraph>Premedication for infusion reactions in patients receiving TRODELVY is recommended<content styleCode="italics">.</content> Have medications and emergency equipment to treat infusion-related reactions, including anaphylaxis, available for immediate use when administering TRODELVY <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Closely monitor patients for hypersensitivity and infusion-related reactions during each TRODELVY infusion and for at least 30 minutes after completion of each infusion <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>Permanently discontinue TRODELVY for Grade 4 infusion-related reactions <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="c954314a-2e13-4a76-84e4-43fad7883b0e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Nausea and Vomiting</title>
                     <text>
                        <paragraph>TRODELVY is emetogenic and can cause severe nausea and vomiting. Nausea occurred in 64% of all patients treated with TRODELVY. Grade 3–4 nausea occurred in 3% of patients.</paragraph>
                        <paragraph>Vomiting occurred in 35% of all patients treated with TRODELVY. Grade 3–4 vomiting occurred in 2% of these patients.</paragraph>
                        <paragraph>Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK<sub>1</sub> receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV) [<content styleCode="italics">see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>Withhold TRODELVY doses for Grade 3 nausea or Grade 3–4 vomiting at the time of scheduled treatment administration and resume with additional supportive measures when resolved to ≤ Grade 1 <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="6bcb7bab-ae35-45e8-b1f9-c5492aa00af9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity</title>
                     <text>
                        <paragraph>Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia; and may be at increased risk for other adverse reactions when treated with TRODELVY.</paragraph>
                        <paragraph>The incidence of neutropenia and anemia was analyzed in 948 patients who received TRODELVY and had UGT1A1 genotype results. In patients homozygous for the UGT1A1 *28 allele (n=112), the incidence of Grade 3–4 neutropenia was 58%. In patients heterozygous for the UGT1A1*28 allele (n=420), the incidence of Grade 3–4 neutropenia was 49%. In patients homozygous for the wild-type allele (n=416), the incidence of Grade 3–4 neutropenia was 43% <content styleCode="italics">[see <linkHtml href="#S12.5">Clinical Pharmacology (12.5)</linkHtml>]</content>. In patients homozygous for the UGT1A1 *28 allele, the incidence of Grade 3–4 anemia was 21%. In patients heterozygous for the UGT1A1*28 allele, the incidence of Grade 3–4 anemia was 10%. In patients homozygous for the wild-type allele, the incidence of Grade 3–4 anemia was 9%.</paragraph>
                        <paragraph>The  median time to first neutropenia including febrile neutropenia was 9 days in patients homozygous for the UGT1A1*28 allele, 15 days in patients heterozygous for the UGT1A1*28 allele, and 20 days in patients homozygous for the wild-type allele. The median time to first anemia was 21 days in patients homozygous for the UGT1A1*28 allele, 25 days in patients heterozygous for the UGT1A1*28 allele, and 28 days in patients homozygous for the wild-type allele.</paragraph>
                        <paragraph>Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue TRODELVY based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 enzyme activity <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="d4ca0c5f-3ab2-4a83-b63c-b8f711bcd60d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Embryo-Fetal Toxicity </title>
                     <text>
                        <paragraph>Based on its mechanism of action, TRODELVY can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells <content styleCode="italics">[see <linkHtml href="#S12.1">Clinical Pharmacology (12.1)</linkHtml> and <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>].</content> Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="b0db5079-2869-4213-b372-20717622d9ac"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in greater detail in other sections of the label:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Neutropenia <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Diarrhea <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Hypersensitivity and Infusion-Related Reactions <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Nausea and Vomiting <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence ≥25%) are (including laboratory abnormalities) were decreased leukocyte count, decreased neutrophil count, decreased hemoglobin, diarrhea, nausea, decreased lymphocyte count, fatigue, alopecia, constipation, increased glucose, decreased albumin, vomiting, decreased appetite, decreased creatinine clearance, increased alkaline phosphatase, decreased magnesium, decreased potassium, and decreased sodium. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at 1-888-983-4668 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="924d4703-4261-4f9e-9e9f-9c896b940061"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>The pooled safety population described in the Warnings and Precautions section reflect exposure to TRODELVY in 1063 patients, which included 366 patients with mTNBC and 322 patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer  from IMMU-132-01, ASCENT, and TROPiCS-02; and 375 patients with other tumor types. TRODELVY was administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles at doses of 10 mg/kg until disease progression or unacceptable toxicity. Among the 1063 patients treated with TRODELVY, the median duration of treatment was 4.1 months (range: 0 to 63 months). In this pooled safety population, the most common (≥ 25%) adverse reactions including laboratory abnormalities were decreased leukocyte count (84%), decreased neutrophil count (75%), decreased hemoglobin (69%), diarrhea (64%), nausea (64%), decreased lymphocyte count (63%), fatigue (51%), alopecia (45%), constipation (37%), increased glucose (37%), decreased albumin (35%), vomiting (35%), decreased appetite (30%), decreased creatinine clearance (28%), increased alkaline phosphatase (28%), decreased magnesium (27%), decreased potassium (26%), and decreased sodium (26%).</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="0413742a-0de8-4c7d-b084-7a031d6e8f03"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Locally Advanced or Metastatic Triple-Negative Breast Cancer</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                           <component>
                              <section>
                                 <id root="3e825cad-af3e-4319-9ed4-fcf4f8983a5a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">ASCENT Study</content>
                                    </paragraph>
                                    <paragraph>The safety of TRODELVY was evaluated in a randomized, active-controlled, open-label study (ASCENT) in patients with mTNBC who had previously received a taxane and at least two prior chemotherapies. Patients were randomized (1:1) to receive either TRODELVY (n=258) or single agent chemotherapy (n=224) and were treated until disease progression or unacceptable toxicity <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>. For patients treated with TRODELVY, the median duration of treatment was 4.4 months (range: 0 to 23 months).</paragraph>
                                    <paragraph>Serious adverse reactions occurred in 27% of patients receiving TRODELVY.  Serious adverse reactions in &gt; 1% of patients receiving TRODELVY included neutropenia (7%), diarrhea (4%), and pneumonia (3%).  Fatal adverse reactions occurred in 1.2% of patients who received TRODELVY, including respiratory failure (0.8%) and pneumonia (0.4%).  TRODELVY was permanently discontinued for adverse reactions in 5% of patients.  Adverse reactions leading to permanent discontinuation in ≥ 1 % of patients who received TRODELVY were pneumonia (1%) and fatigue (1%).</paragraph>
                                    <paragraph>Adverse reactions leading to a treatment interruption of TRODELVY occurred in 63% of patients. The most frequent (≥5%) adverse reactions leading to a treatment interruption were neutropenia (47%), diarrhea (5%), respiratory infection (5%), and leukopenia (5%).</paragraph>
                                    <paragraph>Adverse reactions leading to a dose reduction of TRODELVY occurred in 22% of patients. The most frequent (&gt;4%) adverse reactions leading to a dose reduction were neutropenia (11%) and diarrhea (5%).</paragraph>
                                    <paragraph>Granulocyte-colony stimulating factor (G-CSF) was used in 44% of patients who received TRODELVY.</paragraph>
                                    <paragraph>Tables 3 and 4 summarize adverse reactions and laboratory abnormalities, respectively, in the ASCENT study.</paragraph>
                                    <table width="85%">
                                       <caption>Table 3: Adverse Reactions in ≥ 10% of Patients with mTNBC in ASCENT</caption>
                                       <col width="20%" align="left" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <thead>
                                          <tr styleCode="Botrule">
                                             <th styleCode="Lrule Rrule"/>
                                             <th styleCode="Rrule" colspan="2">TRODELVY (n=258)</th>
                                             <th styleCode="Rrule" colspan="2">Single Agent Chemotherapy (n=224)</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Lrule Rrule">Adverse Reaction</th>
                                             <th styleCode="Rrule">All Grades<br/>%</th>
                                             <th styleCode="Rrule">Grade 3 – 4<br/>%</th>
                                             <th styleCode="Rrule">All Grades<br/>%</th>
                                             <th styleCode="Rrule">Grade 3 – 4<br/>%</th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td colspan="5">*Single agent chemotherapy included one of the following single-agents: eribulin (n=139), capecitabine (n=33), gemcitabine (n=38), or vinorelbine (except if patient had ≥ Grade 2 neuropathy, n=52).</td>
                                          </tr>
                                          <tr>
                                             <td colspan="5">Graded per NCI CTCAE v.5.0.</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Gastrointestinal disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Diarrhea</td>
                                             <td styleCode="Rrule">59</td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">17</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Nausea</td>
                                             <td styleCode="Rrule">57</td>
                                             <td styleCode="Rrule">3</td>
                                             <td styleCode="Rrule">26</td>
                                             <td styleCode="Rrule">0.4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Vomiting</td>
                                             <td styleCode="Rrule">33</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Constipation</td>
                                             <td styleCode="Rrule">37</td>
                                             <td styleCode="Rrule">0.4</td>
                                             <td styleCode="Rrule">23</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Abdominal Pain</td>
                                             <td styleCode="Rrule">30</td>
                                             <td styleCode="Rrule">3</td>
                                             <td styleCode="Rrule">12</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Stomatitis<footnote>Including stomatitis, glossitis, mouth ulceration, and mucosal inflammation</footnote>
                                             </td>
                                             <td styleCode="Rrule">17</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">13</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">General disorders and administration site conditions</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Fatigue<footnote>Including fatigue and asthenia</footnote>
                                             </td>
                                             <td styleCode="Rrule">65</td>
                                             <td styleCode="Rrule">6</td>
                                             <td styleCode="Rrule">50</td>
                                             <td styleCode="Rrule">9</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Pyrexia</td>
                                             <td styleCode="Rrule">15</td>
                                             <td styleCode="Rrule">0.4</td>
                                             <td styleCode="Rrule">14</td>
                                             <td styleCode="Rrule">2</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Infections and infestation</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Urinary tract infection</td>
                                             <td styleCode="Rrule">13</td>
                                             <td styleCode="Rrule">0.4</td>
                                             <td styleCode="Rrule">8</td>
                                             <td styleCode="Rrule">0.4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Upper respiratory tract infection</td>
                                             <td styleCode="Rrule">12</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">3</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Metabolism and nutrition disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased appetite</td>
                                             <td styleCode="Rrule">28</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">21</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Back pain</td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">1</td>
                                             <td styleCode="Rrule">14</td>
                                             <td styleCode="Rrule">2</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Arthralgia</td>
                                             <td styleCode="Rrule">12</td>
                                             <td styleCode="Rrule">0.4</td>
                                             <td styleCode="Rrule">7</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Nervous system disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Headache</td>
                                             <td styleCode="Rrule">18</td>
                                             <td styleCode="Rrule">0.8</td>
                                             <td styleCode="Rrule">13</td>
                                             <td styleCode="Rrule">0.4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Dizziness</td>
                                             <td styleCode="Rrule">10</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">7</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Psychiatric disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Insomnia</td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">5</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Cough</td>
                                             <td styleCode="Rrule">24</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">18</td>
                                             <td styleCode="Rrule">0.4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Alopecia</td>
                                             <td styleCode="Rrule">47</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Rash</td>
                                             <td styleCode="Rrule">12</td>
                                             <td styleCode="Rrule">0.4</td>
                                             <td styleCode="Rrule">5</td>
                                             <td styleCode="Rrule">0.4</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Pruritus</td>
                                             <td styleCode="Rrule">10</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">3</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <table width="80%">
                                       <caption>Table 4: Laboratory Abnormalities in &gt; 10% of Patients with mTNBC in ASCENT </caption>
                                       <col width="40%" align="left" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule">Laboratory Abnormality</th>
                                             <th styleCode="Botrule Rrule" colspan="2">TRODELVY<br/>(n=258)</th>
                                             <th styleCode="Botrule Rrule" colspan="2">Single Agent Chemotherapy<br/>(n=224)</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Lrule Rrule"/>
                                             <th styleCode="Rrule" align="center">All Grades<br/>(%)</th>
                                             <th styleCode="Rrule">Grade 3 – 4<br/>(%)</th>
                                             <th styleCode="Rrule">All Grades<br/>(%)</th>
                                             <th styleCode="Rrule">Grade 3 – 4<br/>(%)</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Hematology</content>
                                             </td>
                                             <td colspan="4" styleCode="Rrule"/>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased hemoglobin</td>
                                             <td styleCode="Rrule">94</td>
                                             <td styleCode="Rrule">9</td>
                                             <td styleCode="Rrule">57</td>
                                             <td styleCode="Rrule">6</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased lymphocyte count</td>
                                             <td styleCode="Rrule">88</td>
                                             <td styleCode="Rrule">31</td>
                                             <td styleCode="Rrule">40</td>
                                             <td styleCode="Rrule">24</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased leukocyte count</td>
                                             <td styleCode="Rrule">86</td>
                                             <td styleCode="Rrule">41</td>
                                             <td styleCode="Rrule">53</td>
                                             <td styleCode="Rrule">25</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased neutrophil count</td>
                                             <td styleCode="Rrule">78</td>
                                             <td styleCode="Rrule">49</td>
                                             <td styleCode="Rrule">48</td>
                                             <td styleCode="Rrule">36</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased platelet count</td>
                                             <td styleCode="Rrule">23</td>
                                             <td styleCode="Rrule">1.2</td>
                                             <td styleCode="Rrule">25</td>
                                             <td styleCode="Rrule">2.7</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Chemistry</content>
                                             </td>
                                             <td colspan="4" styleCode="Rrule"/>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased glucose</td>
                                             <td styleCode="Rrule">49</td>
                                             <td styleCode="Rrule">2.3</td>
                                             <td styleCode="Rrule">43</td>
                                             <td styleCode="Rrule">2.8</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased calcium</td>
                                             <td styleCode="Rrule">36</td>
                                             <td styleCode="Rrule">1.6</td>
                                             <td styleCode="Rrule">21</td>
                                             <td styleCode="Rrule">1.4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased magnesium</td>
                                             <td styleCode="Rrule">33</td>
                                             <td styleCode="Rrule">0.4</td>
                                             <td styleCode="Rrule">20</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased potassium</td>
                                             <td styleCode="Rrule">33</td>
                                             <td styleCode="Rrule">4.3</td>
                                             <td styleCode="Rrule">28</td>
                                             <td styleCode="Rrule">0.9</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased albumin</td>
                                             <td styleCode="Rrule">32</td>
                                             <td styleCode="Rrule">0.8</td>
                                             <td styleCode="Rrule">25</td>
                                             <td styleCode="Rrule">1.4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased aspartate aminotransferase</td>
                                             <td styleCode="Rrule">27</td>
                                             <td styleCode="Rrule">1.2</td>
                                             <td styleCode="Rrule">32</td>
                                             <td styleCode="Rrule">1.4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased alanine aminotransferase</td>
                                             <td styleCode="Rrule">26</td>
                                             <td styleCode="Rrule">1.2</td>
                                             <td styleCode="Rrule">26</td>
                                             <td styleCode="Rrule">1.8</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased alkaline phosphatase</td>
                                             <td styleCode="Rrule">26</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">17</td>
                                             <td styleCode="Rrule">0.5</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased phosphate</td>
                                             <td styleCode="Rrule">26</td>
                                             <td styleCode="Rrule">7.8</td>
                                             <td styleCode="Rrule">20</td>
                                             <td styleCode="Rrule">3.3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased sodium</td>
                                             <td styleCode="Rrule">22</td>
                                             <td styleCode="Rrule">0.4</td>
                                             <td styleCode="Rrule">17</td>
                                             <td styleCode="Rrule">0.5</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased lactate dehydrogenase</td>
                                             <td styleCode="Rrule">18</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">22</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Decreased glucose</td>
                                             <td styleCode="Rrule">10</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">3.2</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250331"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="c37afb0c-081c-4c92-a480-224b94c46ffa"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline italics">Study IMMU-132-01</content>
                                    </paragraph>
                                    <paragraph>The safety of TRODELVY was evaluated in a single-arm, open-label study (IMMU-132-01) in patients with mTNBC and other malignancies, which included 108 patients with mTNBC who had received at least two prior anticancer therapies for metastatic disease <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>.  TRODELVY was administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles at doses up to 10 mg/kg until disease progression or unacceptable toxicity.  The median treatment duration in these 108 patients was 5.1 months (range: 0 to 51 months).</paragraph>
                                    <paragraph>Serious adverse reactions occurred in 31% of the patients. Serious adverse reactions in &gt; 1% of patients receiving TRODELVY included febrile neutropenia (6%) vomiting (5%), nausea (3%), dyspnea (3%), diarrhea (4%), anemia (2%), pleural effusion, neutropenia, pneumonia, dehydration (each 2%).</paragraph>
                                    <paragraph>TRODELVY was permanently discontinued for adverse reactions in 2% of patients. Adverse reactions leading to permanent discontinuation were anaphylaxis, anorexia/fatigue, headache (each 0.9%). Forty- five percent (45%) of patients experienced an adverse reaction leading to treatment interruption. The most common adverse reaction leading to treatment interruption was neutropenia (33%). Adverse reactions leading to dose reduction occurred in 33% of patients treated with TRODELVY, with 24% having one dose reduction, and 9% with two dose reductions. The most common adverse reaction leading to dose reductions was neutropenia/febrile neutropenia.</paragraph>
                                    <paragraph>Tables 5 and 6 summarize adverse reactions and laboratory abnormalities occurring in ≥ 10% of patients with mTNBC in the IMMU-132-01 study.</paragraph>
                                    <table width="85%">
                                       <caption>Table 5: Adverse Reactions in ≥ 10% of Patients with mTNBC in IMMU-132-01</caption>
                                       <col width="60%" align="left" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <thead>
                                          <tr styleCode="Botrule">
                                             <th styleCode="Lrule Rrule" rowspan="2" align="center">Adverse Reaction</th>
                                             <th styleCode="Rrule" colspan="2">TRODELVY<br/>(n=108)</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Rrule" align="center">Grade 1–4<br/>(%)</th>
                                             <th styleCode="Rrule">Grade 3–4<br/>(%)</th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td colspan="3">Graded per NCI CTCAE v. 4.0</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Any adverse reaction</content>
                                             </td>
                                             <td styleCode="Rrule">100</td>
                                             <td styleCode="Rrule">71</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Gastrointestinal disorders</content>
                                             </td>
                                             <td styleCode="Rrule">95</td>
                                             <td styleCode="Rrule">21</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Nausea</td>
                                             <td styleCode="Rrule">69</td>
                                             <td styleCode="Rrule">6</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Diarrhea</td>
                                             <td styleCode="Rrule">63</td>
                                             <td styleCode="Rrule">9</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Vomiting</td>
                                             <td styleCode="Rrule">49</td>
                                             <td styleCode="Rrule">6</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Constipation</td>
                                             <td styleCode="Rrule">34</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Abdominal pain<footnote>Including abdominal pain, distention, pain (upper), discomfort, tenderness.</footnote>
                                             </td>
                                             <td styleCode="Rrule">26</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Mucositis<footnote>Including stomatitis, esophagitis, and mucosal inflammation</footnote>
                                             </td>
                                             <td styleCode="Rrule">14</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">General disorders and administration site conditions</content>
                                             </td>
                                             <td styleCode="Rrule">77</td>
                                             <td styleCode="Rrule">9</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Fatigue<footnote>Including fatigue and asthenia.</footnote>
                                             </td>
                                             <td styleCode="Rrule">57</td>
                                             <td styleCode="Rrule">8</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Edema<footnote>Including edema; and peripheral, localized, and periorbital edema</footnote>
                                             </td>
                                             <td styleCode="Rrule">19</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Pyrexia</td>
                                             <td styleCode="Rrule">14</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Metabolism and nutrition disorders</content>
                                             </td>
                                             <td styleCode="Rrule">68</td>
                                             <td styleCode="Rrule">22</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Decreased appetite</td>
                                             <td styleCode="Rrule">30</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Dehydration</td>
                                             <td styleCode="Rrule">13</td>
                                             <td styleCode="Rrule">5</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                             </td>
                                             <td styleCode="Rrule">63</td>
                                             <td styleCode="Rrule">4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Alopecia</td>
                                             <td styleCode="Rrule">38</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Rash<footnote>Including rash; maculopapular, erythematous, generalized rash; dermatitis acneiform; skin disorder, irritation, and exfoliation</footnote>
                                             </td>
                                             <td styleCode="Rrule">31</td>
                                             <td styleCode="Rrule">3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Pruritus</td>
                                             <td styleCode="Rrule">17</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Dry Skin</td>
                                             <td styleCode="Rrule">15</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Nervous system disorders</content>
                                             </td>
                                             <td styleCode="Rrule">56</td>
                                             <td styleCode="Rrule">4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Headache</td>
                                             <td styleCode="Rrule">23</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Dizziness</td>
                                             <td styleCode="Rrule">22</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Neuropathy<footnote>Including gait disturbance, hypoesthesia, muscular weakness, paresthesia, peripheral and sensory neuropathy</footnote>
                                             </td>
                                             <td styleCode="Rrule">24</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Dysgeusia</td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Infections and infestations</content>
                                             </td>
                                             <td styleCode="Rrule">55</td>
                                             <td styleCode="Rrule">12</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Urinary Tract Infection</td>
                                             <td styleCode="Rrule">21</td>
                                             <td styleCode="Rrule">3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Respiratory Infection<footnote>Including lower and upper respiratory tract infection, pneumonia, influenza, viral upper respiratory infection, bronchitis and respiratory syncytial virus infection</footnote>
                                             </td>
                                             <td styleCode="Rrule">26</td>
                                             <td styleCode="Rrule">3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                             </td>
                                             <td styleCode="Rrule">54</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Back pain</td>
                                             <td styleCode="Rrule">23</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Arthralgia</td>
                                             <td styleCode="Rrule">17</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Pain in extremity</td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                             </td>
                                             <td styleCode="Rrule">54</td>
                                             <td styleCode="Rrule">5</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Cough<footnote>Includes cough and productive cough</footnote>
                                             </td>
                                             <td styleCode="Rrule">22</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">  Dyspnea<footnote>Includes dyspnea and exertional dyspnea </footnote>
                                             </td>
                                             <td styleCode="Rrule">21</td>
                                             <td styleCode="Rrule">3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Psychiatric disorders</content>
                                             </td>
                                             <td styleCode="Rrule">26</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">  Insomnia</td>
                                             <td styleCode="Rrule">13</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <table width="85%">
                                       <caption>Table 6: Laboratory Abnormalities observed in ≥ 10% of Patients while receiving TRODELVY in IMMU-132-01</caption>
                                       <col width="60%" align="left" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <col width="20%" align="center" valign="middle"/>
                                       <thead>
                                          <tr styleCode="Botrule">
                                             <th styleCode="Lrule Rrule" rowspan="2">Laboratory Abnormality</th>
                                             <th styleCode="Rrule" colspan="2">TRODELVY<br/>(n=108)</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Rrule" align="center">All Grades<br/>(%)</th>
                                             <th styleCode="Rrule">Grade 3–4<br/>(%)</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="3">
                                                <content styleCode="bold">Hematology</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased hemoglobin</td>
                                             <td styleCode="Rrule">93</td>
                                             <td styleCode="Rrule">6</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased leukocyte count</td>
                                             <td styleCode="Rrule">91</td>
                                             <td styleCode="Rrule">26</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased neutrophil count</td>
                                             <td styleCode="Rrule">82</td>
                                             <td styleCode="Rrule">32</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased activated partial thromboplastin time</td>
                                             <td styleCode="Rrule">60</td>
                                             <td styleCode="Rrule">12</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased platelet count</td>
                                             <td styleCode="Rrule">30</td>
                                             <td styleCode="Rrule">3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="3">
                                                <content styleCode="bold">Chemistry</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased alkaline phosphatase</td>
                                             <td styleCode="Rrule">57</td>
                                             <td styleCode="Rrule">2</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased magnesium</td>
                                             <td styleCode="Rrule">51</td>
                                             <td styleCode="Rrule">3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased calcium</td>
                                             <td styleCode="Rrule">49</td>
                                             <td styleCode="Rrule">3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased aspartate aminotransferase</td>
                                             <td styleCode="Rrule">45</td>
                                             <td styleCode="Rrule">3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased albumin</td>
                                             <td styleCode="Rrule">39</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased alanine aminotransferase</td>
                                             <td styleCode="Rrule">35</td>
                                             <td styleCode="Rrule">2</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased glucose</td>
                                             <td styleCode="Rrule">31</td>
                                             <td styleCode="Rrule">2.8</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased phosphate</td>
                                             <td styleCode="Rrule">29</td>
                                             <td styleCode="Rrule">5</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decrease magnesium</td>
                                             <td styleCode="Rrule">27</td>
                                             <td styleCode="Rrule">1.9</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased phosphate</td>
                                             <td styleCode="Rrule">27</td>
                                             <td styleCode="Rrule">6.5</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased sodium</td>
                                             <td styleCode="Rrule">25</td>
                                             <td styleCode="Rrule">4.7</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased potassium</td>
                                             <td styleCode="Rrule">24</td>
                                             <td styleCode="Rrule">3.7</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Decreased glucose</td>
                                             <td styleCode="Rrule">19</td>
                                             <td styleCode="Rrule">2</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250331"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f182c3a9-3b65-45a1-ba37-403958f792b0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                           <component>
                              <section>
                                 <id root="8bd84f18-cb6c-4019-ab73-97ec2c295c07"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">TROPiCS-02 Study</content>
                                    </paragraph>
                                    <paragraph>The safety of TRODELVY was evaluated in a randomized, active-controlled, open-label, study (TROPiCS-02) in patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer whose disease has progressed after the following in any setting: a CDK 4/6 inhibitor, endocrine therapy, and a taxane; patients received at least two prior chemotherapies in the metastatic setting (one of which could be in the neoadjuvant or adjuvant setting if progression occurred within 12 months). Patients were randomized (1:1) to receive either TRODELVY (n=268) or single agent chemotherapy (n=249) and were treated until disease progression or unacceptable toxicity <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>. For patients treated with TRODELVY, the median duration of treatment was 4.1 months (range: 0 to 63 months).</paragraph>
                                    <paragraph>Serious adverse reactions occurred in 28% of patients receiving TRODELVY.  Serious adverse reactions in &gt; 1% of patients receiving TRODELVY included diarrhea (5%), febrile neutropenia (4%), neutropenia (3%), abdominal pain, colitis, neutropenic colitis, pneumonia, and vomiting (each 2%). Fatal adverse reactions occurred in 2% of patients who received TRODELVY including arrhythmia, COVID-19, nervous system disorder, pulmonary embolism, and septic shock (each 0.4%). TRODELVY was permanently discontinued for adverse reactions in 6% of patients. The most frequent (≥ 0.5%) adverse reactions leading to permanent discontinuation in patients who received TRODELVY were asthenia, general physical health deterioration, and neutropenia (each 0.7%).</paragraph>
                                    <paragraph>Adverse reactions leading to a treatment interruptions of TRODELVY occurred in 66% of patients. The most frequent (≥ 5%) adverse reaction leading to treatment interruption was neutropenia (50%).</paragraph>
                                    <paragraph>Adverse reaction leading to a dose reduction of TRODELVY occurred in 33% of patients. The most frequent (&gt; 5%) adverse reaction leading to dose reduction were neutropenia (16%) and diarrhea (8%). G-CSF was used in 54% of patients who received TRODELVY.</paragraph>
                                    <paragraph>Tables 7 and 8 summarize adverse reactions and laboratory abnormalities in the TROPiCS-02 study.</paragraph>
                                    <table width="85%">
                                       <caption>Table 7: Adverse Reactions in ≥ 10% of Patients with HR+/HER2- mBC in TROPiCS-02</caption>
                                       <col width="20%" align="left" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <thead>
                                          <tr styleCode="Botrule">
                                             <th styleCode="Lrule Rrule"/>
                                             <th styleCode="Rrule" colspan="2">TRODELVY<br/> (n=268)</th>
                                             <th styleCode="Rrule" colspan="2">Single Agent Chemotherapy<br/> (n=249)</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Lrule Rrule">Adverse Reaction</th>
                                             <th styleCode="Rrule">All Grades<br/>%</th>
                                             <th styleCode="Rrule">Grade 3 – 4<br/>%</th>
                                             <th styleCode="Rrule">All Grades<br/>%</th>
                                             <th styleCode="Rrule">Grade 3 – 4<br/>%</th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td colspan="5">*Single agent chemotherapy included one of the following single-agents: eribulin (n=130), vinorelbine (n=63), gemcitabine (n=56), or capecitabine (n=22).</td>
                                          </tr>
                                          <tr>
                                             <td colspan="5">Graded per NCI CTCAE v.5.0.</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Gastrointestinal disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Diarrhea</td>
                                             <td styleCode="Rrule">62</td>
                                             <td styleCode="Rrule">10</td>
                                             <td styleCode="Rrule">23</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Nausea</td>
                                             <td styleCode="Rrule">59</td>
                                             <td styleCode="Rrule">1</td>
                                             <td styleCode="Rrule">35</td>
                                             <td styleCode="Rrule">3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Constipation</td>
                                             <td styleCode="Rrule">34</td>
                                             <td styleCode="Rrule">1</td>
                                             <td styleCode="Rrule">25</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Vomiting</td>
                                             <td styleCode="Rrule">23</td>
                                             <td styleCode="Rrule">1</td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">2</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Abdominal Pain</td>
                                             <td styleCode="Rrule">20</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">14</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Dyspepsia<footnote>Including dyspepsia, gastroesophageal reflux disease.</footnote>
                                             </td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">6</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">General disorders and administration site conditions</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Fatigue<footnote>Including fatigue, asthenia.</footnote>
                                             </td>
                                             <td styleCode="Rrule">60</td>
                                             <td styleCode="Rrule">8</td>
                                             <td styleCode="Rrule">51</td>
                                             <td styleCode="Rrule">4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Metabolism and nutrition disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased appetite</td>
                                             <td styleCode="Rrule">21</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">21</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Hypokalemia</td>
                                             <td styleCode="Rrule">10</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">4</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Arthralgia</td>
                                             <td styleCode="Rrule">15</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">12</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Nervous system disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Headache</td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">1</td>
                                             <td styleCode="Rrule">15</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Dyspnea <footnote>Including dyspnea; exertional dyspnea</footnote>
                                             </td>
                                             <td styleCode="Rrule">20</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">17</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Cough</td>
                                             <td styleCode="Rrule">12</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">7</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Alopecia</td>
                                             <td styleCode="Rrule">48</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">19</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Pruritus</td>
                                             <td styleCode="Rrule">12</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Other clinically significant adverse reactions in TROPiCS-02 (≤ 10%) include: hypotension (5%), pain (5%), rhinorrhea (5%), hypocalcemia (3%), nasal congestion (3%), skin hyperpigmentation, (3%), colitis or neutropenic colitis (2%), hyponatremia (2%), pneumonia (2%), proteinuria (1%), enteritis (0.4%).</paragraph>
                                    <table width="80%">
                                       <caption>Table 8: Laboratory Abnormalities in &gt; 10% of Patients with HR+/HER2- mBC in TROPiCS-02</caption>
                                       <col width="40%" align="left" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule">Laboratory Abnormality</th>
                                             <th styleCode="Botrule Rrule" colspan="2">TRODELVY<br/>(n=268)</th>
                                             <th styleCode="Botrule Rrule" colspan="2">Single Agent Chemotherapy<br/>(n=249)</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Lrule Rrule"/>
                                             <th styleCode="Rrule" align="center">All Grades<br/>(%)</th>
                                             <th styleCode="Rrule">Grade 3 – 4<br/>(%)</th>
                                             <th styleCode="Rrule">All Grades<br/>(%)</th>
                                             <th styleCode="Rrule">Grade 3 – 4<br/>(%)</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule">
                                                <content styleCode="bold">Hematology</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased leukocyte count</td>
                                             <td styleCode="Rrule">88</td>
                                             <td styleCode="Rrule">38</td>
                                             <td styleCode="Rrule">73</td>
                                             <td styleCode="Rrule">26</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased neutrophil count</td>
                                             <td styleCode="Rrule">83</td>
                                             <td styleCode="Rrule">53</td>
                                             <td styleCode="Rrule">67</td>
                                             <td styleCode="Rrule">40</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased hemoglobin</td>
                                             <td styleCode="Rrule">73</td>
                                             <td styleCode="Rrule">8</td>
                                             <td styleCode="Rrule">59</td>
                                             <td styleCode="Rrule">5</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased lymphocyte count</td>
                                             <td styleCode="Rrule">65</td>
                                             <td styleCode="Rrule">21</td>
                                             <td styleCode="Rrule">47</td>
                                             <td styleCode="Rrule">14</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased platelet count</td>
                                             <td styleCode="Rrule">21</td>
                                             <td styleCode="Rrule">1</td>
                                             <td styleCode="Rrule">30</td>
                                             <td styleCode="Rrule">4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Eosinophilia</td>
                                             <td styleCode="Rrule">13</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">4</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" styleCode="Lrule Rrule">
                                                <content styleCode="bold">Chemistry</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased glucose</td>
                                             <td styleCode="Rrule">37</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">31</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased albumin</td>
                                             <td styleCode="Rrule">32</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">27</td>
                                             <td styleCode="Rrule">0.4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased creatinine clearance</td>
                                             <td styleCode="Rrule">24</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">19</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased alkaline phosphatase</td>
                                             <td styleCode="Rrule">23</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">23</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased potassium</td>
                                             <td styleCode="Rrule">22</td>
                                             <td styleCode="Rrule">3</td>
                                             <td styleCode="Rrule">12</td>
                                             <td styleCode="Rrule">0.4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased alanine aminotransferase</td>
                                             <td styleCode="Rrule">21</td>
                                             <td styleCode="Rrule">1</td>
                                             <td styleCode="Rrule">31</td>
                                             <td styleCode="Rrule">2</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased sodium</td>
                                             <td styleCode="Rrule">19</td>
                                             <td styleCode="Rrule">1</td>
                                             <td styleCode="Rrule">17</td>
                                             <td styleCode="Rrule">0.4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased magnesium</td>
                                             <td styleCode="Rrule">18</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">15</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Decreased phosphate</td>
                                             <td styleCode="Rrule">17</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">10</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased phosphate</td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased lactate dehydrogenase</td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">28</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Increased aspartate aminotransferase</td>
                                             <td styleCode="Rrule">15</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">25</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Increased potassium</td>
                                             <td styleCode="Rrule">14</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">9</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250331"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="0cc436de-fc6c-407f-8cd9-a2938192c8c1"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>UGT1A1 inhibitors or inducers: Avoid concomitant use. (<linkHtml href="#S7">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="14ab5673-7873-4468-8114-47af7ec91075"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effect of Other Drugs on TRODELVY</title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="5b41be7f-043e-449f-b02b-bcb44dd62b03"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">UGT1A1 Inhibitors</content>
                              </paragraph>
                              <paragraph>Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38 <content styleCode="italics">[see <linkHtml href="#S5.5">Warning and Precaution (5.5)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3</linkHtml>, <linkHtml href="#S12.5">12.5)</linkHtml>]</content>. Avoid administering UGT1A1 inhibitors with TRODELVY.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="7913e61e-9958-489d-bfff-31e4864be1d3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">UGT1A1 Inducers</content>
                              </paragraph>
                              <paragraph>Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers <content styleCode="italics">[see <linkHtml href="#S5.5">Warning and Precaution (5.5)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3</linkHtml>, <linkHtml href="#S12.5">12.5)</linkHtml>]</content>. Avoid administering UGT1A1 inducers with TRODELVY.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="3f6314b2-de13-4c2b-910c-4429ce4e71e8"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Lactation: Advise not to breastfeed. (<linkHtml href="#S8.2">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="0987d848-08d9-4c60-b23e-21b7792fa9dd"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="6d70e3d5-e1b9-4b10-89b8-fe8792b92b3d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on its mechanism of action, TRODELVY can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. TRODELVY contains a genotoxic component, SN-38, and is toxic to rapidly dividing cells <content styleCode="italics">[see <linkHtml href="#S12.1">Clinical Pharmacology (12.1)</linkHtml> and <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>]</content>. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 – 4% and 15 – 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b7b41fef-1ac7-465d-9d41-252c383cc8a8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                           <component>
                              <section>
                                 <id root="9d4946fc-c1b9-411d-bfe5-aa6982c86c18"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal data</content>
                                    </paragraph>
                                    <paragraph>There were no reproductive and developmental toxicology studies conducted with sacituzumab govitecan-hziy.</paragraph>
                                 </text>
                                 <effectiveTime value="20250331"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="193eb929-4095-403c-898f-85650b64778e"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="f3c9cb1a-b25a-4df7-833d-74b8faf13a57"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information regarding the presence of sacituzumab govitecan-hziy or SN-38 in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment and for 1 month after the last dose of TRODELVY.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="1a8c8776-e75d-4241-8579-8aa9450b05ed"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="caf7b62c-65a6-4f9e-b5f7-9ffe4bf85ef0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Verify the pregnancy status of females of reproductive potential prior to the initiation of TRODELVY.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="5fe11756-09ee-42c8-ae5d-347316833fb1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                           <component>
                              <section>
                                 <id root="ed740bd9-d28b-4e84-8b5b-1014680646a2"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>TRODELVY can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>. Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months after the last dose.</paragraph>
                                 </text>
                                 <effectiveTime value="20250331"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="49ebe132-87c9-407e-8cf5-0b9cc7978c51"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Males</content>
                                    </paragraph>
                                    <paragraph>Because of the potential for genotoxicity, advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose.</paragraph>
                                 </text>
                                 <effectiveTime value="20250331"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d7ff893e-5ff2-4dda-a939-4e6c7e963b20"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Infertility</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                           <component>
                              <section>
                                 <id root="2c6d9422-72a7-4ff0-9697-1144416743b9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>Based on findings in animals, TRODELVY may impair fertility in females of reproductive potential <content styleCode="italics">[see <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250331"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="e4fe95af-7885-4453-b5cc-ccddb198c0ab"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of TRODELVY have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="2af90fef-2cdf-4bba-be73-18d1403a08f2"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the 366 patients with TNBC who were treated with TRODELVY, 19% of patients were 65 years and 3% were 75 years and older. Patients 65 and older had an increased incidence of neutropenia, including fatal outcomes. No other differences in safety and effectiveness were observed between patients ≥ 65 years of age and younger patients.</paragraph>
                        <paragraph>Of the 322 patients with HR+/HER2- breast cancer who were treated with TRODELVY, 26% of patients were 65 years and older and 6% were 75 years and older. No overall differences in effectiveness were observed between patients ≥ 65 years of age and younger patients. There was a higher discontinuation rate due to adverse reactions in patients aged 65 years or older (14%) compared with younger patients (3%).</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="7a4daf11-44cf-4140-8026-1cc803e9165c"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>No adjustment to the starting dosage is required when administering TRODELVY to patients with mild hepatic impairment <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>The safety of TRODELVY in patients with moderate (total bilirubin &gt; 1.5 to 3.0 × ULN) or severe (total bilirubin &gt; 3.0 × upper limit of normal [ULN]) hepatic impairment has not been established. TRODELVY has not been tested in patients with AST or ALT &gt; 3 ULN without liver metastases, or AST or ALT &gt; 5 ULN with liver metastases. No recommendations can be made for the starting dosage in these patients.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="b8278a23-e9a2-4dad-a669-3f4ed1f23d93"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In a clinical trial, planned doses of up to 18 mg/kg (approximately 1.8 times the maximum recommended dose of 10 mg/kg) of TRODELVY were administered. In these patients, a higher incidence of severe neutropenia was observed. </paragraph>
               </text>
               <effectiveTime value="20250331"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="a7d2da19-37cf-47b3-bd1a-085b1353fe04"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Sacituzumab govitecan-hziy is a Trop-2 directed antibody and topoisomerase inhibitor conjugate, composed of the following three components:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>the humanized monoclonal antibody, hRS7 IgG1κ (also called sacituzumab), which binds to Trop-2 (the trophoblast cell-surface antigen-2);</item>
                     <item>the drug SN-38, a topoisomerase inhibitor;</item>
                     <item>a hydrolysable linker (called CL2A), which links the humanized monoclonal antibody to SN-38.</item>
                  </list>
                  <paragraph>The recombinant monoclonal antibody is produced by mammalian (murine myeloma) cells, while the small molecule components SN-38 and CL2A are produced by chemical synthesis. Sacituzumab govitecan-hziy contains on average 7 to 8 molecules of SN-38 per antibody molecule. Sacituzumab govitecan-hziy has a molecular weight of approximately 160 kilodaltons. Sacituzumab govitecan-hziy has the following chemical structure.</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="center" valign="middle"/>
                     <tbody>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM1"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>TRODELVY (sacituzumab govitecan-hziy) for injection is a sterile, preservative-free, off-white to yellowish lyophilized powder for intravenous use in a 50 mL clear glass single-dose vial, with a rubber stopper and crimp-sealed with an aluminum flip-off cap.</paragraph>
                  <paragraph>Each single-dose vial of TRODELVY delivers 180 mg sacituzumab govitecan-hziy, 71.7 mg 2-(N-morpholino) ethane sulfonic acid (MES), 1.8 mg polysorbate 80 and 153.99 mg trehalose. Reconstitution with 20 mL of 0.9% Sodium Chloride Injection, USP, results in a concentration of 10 mg/mL with a pH of 6.5.</paragraph>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="trodelvy-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="99d3388a-bc29-4b8f-a701-26fdb767cf1f"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250331"/>
               <component>
                  <section ID="S12.1">
                     <id root="87877ab7-872f-463e-a453-acb46abcb609"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Sacituzumab govitecan-hziy is a Trop-2-directed antibody-drug conjugate. Sacituzumab is a humanized antibody that recognizes Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a linker. Pharmacology data suggest that sacituzumab govitecan-hziy binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. The resulting DNA damage leads to apoptosis and cell death. Sacituzumab govitecan-hziy decreased tumor growth in mouse xenograft models of triple-negative breast cancer. </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="f8dad7d4-489e-41db-b34f-eebe8f60f1f8"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The TRODELVY exposure-response relationships and pharmacodynamic time course for efficacy have not been fully characterized.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="b5c26cbb-16bf-4d82-b683-8750ed7895b3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac electrophysiology</content>
                              </paragraph>
                              <paragraph>The maximum mean change from baseline was 9.7 msec (the upper bound of the two-sided 90% confidence interval is 16.8 msec) at the recommended dose. A positive exposure-response relationship was observed between QTc increases and SN-38 concentrations.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="f6b336d3-f2f7-4fbf-81a4-9643e0364180"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The serum pharmacokinetics of sacituzumab govitecan-hziy and SN-38 were evaluated in patients with mBC who received sacituzumab govitecan-hziy as a single agent at a dose of 10 mg/kg. The pharmacokinetic parameters of sacituzumab govitecan-hziy and free SN-38 are presented in Table 9. </paragraph>
                        <table width="80%">
                           <caption>Table 9: Summary of Mean PK Parameters (CV%) of Sacituzumab Govitecan-hziy and Free SN-38<footnote>Parameters estimated based on population PK analyses </footnote>
                           </caption>
                           <col width="33%" align="center" valign="top"/>
                           <col width="34%" align="center" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Sacituzumab govitecan-hziy<br/>(N=693)</th>
                                 <th styleCode="Rrule">Free SN-38<br/>(N=681)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left">C<sub>max</sub>: maximum serum concentration from 0–168 hours after the first dose</td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left">AUC<sub>0–168</sub>: area under serum concentration curve through 168 hours after the first dose</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">C<sub>max</sub>
                                    </content> [ng/mL]</td>
                                 <td styleCode="Rrule">239000 (11%)</td>
                                 <td styleCode="Rrule">98.0 (45%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">AUC<sub>0–168</sub>
                                    </content> [ng*h/mL]</td>
                                 <td styleCode="Rrule">5640000 (22%)</td>
                                 <td styleCode="Rrule">3696 (56%)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="b0894fe9-90f5-4427-935c-fa0c9a8e8942"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Based on population pharmacokinetic analysis, steady state volume of  distribution of sacituzumab govetican-hziy is 3.6L.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8c0ee5d0-a568-48df-aed6-21861386985f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The median elimination half-life (t<sub>1/2</sub>) of sacituzumab govitecan-hziy and free SN-38 in patients with metastatic triple negative breast cancer was 23.4 and 17.6 hours, respectively. Based on population pharmacokinetic analysis, the estimated mean (%CV) clearance of the sacituzumab govitecan-hziy is 0.13 L/h (12%).</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4f05ff59-38d2-4337-bc85-4a3888da8a85"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism</content>
                              </paragraph>
                              <paragraph>No metabolism studies with sacituzumab govitecan-hziy have been conducted. SN-38 (the small molecule moiety of sacituzumab govitecan-hziy) is metabolized via UGT1A1. The glucuronide metabolite of SN-38 (SN-38G) was detectable in the serum of patients.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ce905d72-2b23-43bc-9329-74834afa1f72"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>Pharmacokinetic analyses in patients treated with TRODELVY did not identify an effect of age (27 to 88 years), race (White, Black, or Asian), or mild renal impairment to moderate renal impairment (CLcr 30 to 89 mL/min) on the pharmacokinetics of sacituzumab govitecan-hziy. Renal elimination is known to contribute minimally to the excretion of SN-38, the small molecule moiety of sacituzumab govitecan-hziy. There are no data on the pharmacokinetics of sacituzumab govitecan-hziy in patients with severe renal impairment (CLcr 15 to 29 mL/min), or end-stage renal disease (CLcr &lt; 15 mL/min).</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4f25d2d5-8092-4cf5-a056-a7083e4d0eff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Patients with Hepatic Impairment</content>
                              </paragraph>
                              <paragraph>The exposure of sacituzumab govitecan-hziy is similar in patients with mild hepatic impairment (total bilirubin ≤ ULN with AST &gt; ULN, or bilirubin &gt;1.0 to ≤ 1.5 ULN with any AST; n=257) to patients with normal hepatic function (total bilirubin and AST &lt; ULN; n=526).</paragraph>
                              <paragraph>Sacituzumab govitecan-hziy and free SN-38 exposures are unknown in patients with moderate (total bilirubin &gt; 1.5 to 3.0 × ULN) or severe (total bilirubin &gt; 3.0 × ULN) hepatic impairment.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="acb64dac-8acd-458b-b0e2-858cfa885c33"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                              <paragraph>No drug-drug interaction studies were conducted with sacituzumab govitecan-hziy or its components. Inhibitors or inducers of UGT1A1 may increase or decrease SN-38 exposure, respectively <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.5">
                     <id root="7d79102f-0029-4abb-b6e6-3ff37f72a17e"/>
                     <code code="66106-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOGENOMICS SECTION"/>
                     <title>12.5 Pharmacogenomics</title>
                     <text>
                        <paragraph>SN-38 is metabolized via UGT1A1 [<content styleCode="italics">see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>
                           </content>]. Genetic variants of the UGT1A1 gene such as the UGT1A1*28 allele lead to reduced UGT1A1 enzyme activity. Individuals who are homozygous or heterozygous for the UGT1A1*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia from TRODELVY compared to individuals who are wildtype (*1/*1) <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>].</content> Approximately 20% of the Black or African American population, 10% of the White population, and 2% of the East Asian population are homozygous for the UGT1A1*28 allele (*28/*28). Approximately 40% of the Black or African American population, 50% of the White population, and 25% of the East Asian population are heterozygous for the UGT1A1*28 allele (*1/*28). Decreased function alleles other than UGT1A1*28 may be present in certain populations.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="539ce086-a294-4593-a2d8-c082e1c09a49"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>12.6 Immunogenicity </title>
                     <text>
                        <paragraph>The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of TRODELVY.</paragraph>
                        <paragraph>During the median 4-month treatment period across clinical studies in patients treated with TRODELVY, 9 (1.1%) of 785 patients developed antibodies to sacituzumab govitecan; 6 of these patients (0.8% of all patients treated with TRODELVY) had neutralizing antibodies against sacituzumab govitecan. Because of the low occurrence of anti-drug antibodies, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of sacituzumab govitecan is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="bf049976-ca20-4d11-8dd2-9070e21142a8"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250331"/>
               <component>
                  <section ID="S13.1">
                     <id root="6114fe72-e33b-4c20-ac52-0a1171dd6ab0"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Carcinogenicity studies have not been conducted with sacituzumab govitecan-hziy.</paragraph>
                        <paragraph>SN-38 was clastogenic in an <content styleCode="italics">in vitro</content> mammalian cell micronucleus test in Chinese hamster ovary cells and was not mutagenic in an <content styleCode="italics">in vitro</content> bacterial reverse mutation (Ames) assay.</paragraph>
                        <paragraph>Fertility studies with sacituzumab govitecan-hziy have not been conducted. In a repeat-dose toxicity study in cynomolgus monkeys, intravenous administration of sacituzumab govitecan-hziy on Day 1 and Day 4 resulted in endometrial atrophy, uterine hemorrhage, increased follicular atresia of the ovary, and atrophy of vaginal epithelial cells at doses ≥ 60 mg/kg (≥ 6 times the human recommended dose of 10 mg/kg based on body weight).</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="b19d944b-d62e-4104-bb22-819dbb5c3300"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250331"/>
               <component>
                  <section ID="S14.1">
                     <id root="3195a11a-d402-431f-a167-6e4dd34acc80"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer</title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="dab8f55f-8fb0-4979-94b5-b0e574c41df6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">ASCENT</content>
                              </paragraph>
                              <paragraph>Efficacy was evaluated in a multicenter, open-label, randomized study (ASCENT; NCT02574455) conducted in 529 patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who had relapsed after at least two prior chemotherapies for breast cancer (one of which could be in the neoadjuvant or adjuvant setting provided progression occurred within a 12 month period). All patients received previous taxane treatment in either the adjuvant, neoadjuvant, or advanced stage unless there was a contraindication or intolerance to taxanes during or at the end of the first taxane cycle. Magnetic resonance imaging (MRI) to determine brain metastases was required prior to enrollment for patients with known or suspected brain metastases. Patients with brain metastases were allowed to enroll up to a pre-defined maximum of 15% of patients in the ASCENT study. Patients with known Gilbert's disease or bone-only disease were excluded.</paragraph>
                              <paragraph>Patients were randomized (1:1) to receive TRODELVY 10 mg/kg as an intravenous infusion on Days 1 and 8 of a 21-day (n=267) or physician's choice of single agent chemotherapy (n=262). Single agent chemotherapy was determined by the investigator before randomization from one of the following choices: eribulin (n=139), capecitabine (n=33), gemcitabine (n=38), or vinorelbine (n=52).</paragraph>
                              <paragraph>Patients were treated until disease progression or unacceptable toxicity. The major efficacy outcome was progression-free survival (PFS) in patients without brain metastases at baseline (i.e., BMNeg) as measured by a blinded, independent, centralized review assessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Additional efficacy measures included PFS for the full population (all patients with and without brain metastases) and overall survival (OS).</paragraph>
                              <paragraph>The median age of patients in the full population (n = 529) was 54 years (range: 27 to 82 years); 99.6% were female; 79% were White, 12% were Black/African American; and 81% of patients were &lt; 65 years of age.  All patients had an ECOG performance status of 0 (43%) or 1 (57%). Forty-two percent of patients had hepatic metastases, 9% were BRCA1/BRCA2 mutational status positive, and 70% were TNBC at diagnosis. Twelve percent had baseline brain metastases previously treated and stable (n=61; 32 on TRODELVY arm and 29 on single agent chemotherapy arm). Overall, 29% of patients had received prior PD-1/PD-L1 therapy. Thirteen percent of patients in the TRODELVY group in the full population received only 1 prior line of systemic therapy in the metastatic setting.</paragraph>
                              <paragraph>The efficacy results are summarized in Table 10 and are shown in Figure 1 and Figure 2. Efficacy results for the subgroup of patients who had received only 1 prior line of systemic therapy in the metastatic setting (in addition to having disease recurrence or progression within 12 months of neoadjuvant/adjuvant systemic therapy) were consistent with those who had received at least two prior lines in the metastatic setting.</paragraph>
                              <table width="85%">
                                 <caption>Table 10: Efficacy Results from ASCENT</caption>
                                 <col width="34%" align="left" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule" colspan="2">All Randomized Patients</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">TRODELVY<br/>n=267</th>
                                       <th styleCode="Rrule">Single Agent Chemotherapy<br/>n=262</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3">CI = Confidence Interval</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Progression-Free Survival<footnote>PFS is defined as the time from the date of randomization to the date of the first radiological disease progression or death due to any cause, whichever comes first.</footnote> per BICR</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Disease Progression or Death (%)</td>
                                       <td styleCode="Rrule">190 (71%)</td>
                                       <td styleCode="Rrule">171 (65%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Median PFS in months (95% CI)</td>
                                       <td styleCode="Rrule">4.8<br/>(4.1, 5.8)</td>
                                       <td styleCode="Rrule">1.7<br/>(1.5, 2.5)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Hazard ratio<footnote ID="t11f2">Stratified log-rank test adjusted for stratification factors: number of prior chemotherapies, presence of known brain metastases at study entry, and region.</footnote> (95% CI)</td>
                                       <td styleCode="Rrule" colspan="2">0.43 (0.35, 0.54)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  p-value</td>
                                       <td styleCode="Rrule" colspan="2">&lt;0.0001</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Overall Survival</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Deaths (%)</td>
                                       <td styleCode="Rrule">179 (67%)</td>
                                       <td styleCode="Rrule">206 (79%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Median OS in months (95% CI)</td>
                                       <td styleCode="Rrule">11.8<br/>(10.5, 13.8)</td>
                                       <td styleCode="Rrule">6.9<br/>(5.9, 7.6)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Hazard ratio<footnoteRef IDREF="t11f2"/> (95% CI)</td>
                                       <td styleCode="Rrule" colspan="2">0.51 (0.41, 0.62)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">  p-value</td>
                                       <td styleCode="Rrule" colspan="2">&lt;0.0001</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="bold">Figure 1: Kaplan-Meier Plot of PFS by BICR (All Randomized Patients) in ASCENT</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM2"/>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure 2: Kaplan-Meier Plot of OS (All Randomized Patients) in ASCENT</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM3"/>
                              </paragraph>
                              <paragraph>An exploratory analysis of PFS in patients with previously treated, stable brain metastases showed a stratified HR of 0.65 (95% CI: 0.35, 1.22). The median PFS in the TRODELVY arm was 2.8 months (95% CI: 1.5, 3.9) and the median PFS with single agent chemotherapy was 1.6 months (95% CI: 1.3, 2.9).  Exploratory OS analysis in the same population showed a stratified HR of 0.87 (95% CI: 0.47, 1.63). The median OS in the TRODELVY arm was 6.8 months (95% CI: 4.7, 14.1) and the median OS with single agent chemotherapy was 7.4 months (95% CI: 4.7, 11.1).</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                           <component>
                              <observationMedia ID="MM2">
                                 <text>Figure 1</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="trodelvy-02.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM3">
                                 <text>Figure 2</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="trodelvy-03.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="12ef73b4-0b3e-49b5-a962-c3cb6e9da90c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">IMMU-132-01</content>
                              </paragraph>
                              <paragraph>The efficacy of TRODELVY was evaluated in a multicenter, single-arm, study (NCT01631552) that enrolled 108 patients with metastatic triple-negative breast cancer (mTNBC) who had received at least two prior anticancer therapies for metastatic disease. Patients with bulky disease, defined as a mass &gt; 7 cm, were not eligible. Patients with treated brain metastases not receiving high dose steroids (&gt; 20 mg prednisone or equivalent) for at least four weeks were eligible. Patients with known Gilbert's disease were excluded.</paragraph>
                              <paragraph>Patients received TRODELVY 10 mg/kg intravenously on Days 1 and 8 of a 21-day treatment cycle. Patients were treated with TRODELVY until disease progression or intolerance to the therapy. Tumor imaging was obtained every 8 weeks, with confirmatory CT/MRI scans obtained 4–6 weeks after an initial partial or complete response, until progression requiring treatment discontinuation. Major efficacy outcome measures were investigator assessed overall response rate (ORR) using RECIST 1.1 and duration of response.</paragraph>
                              <paragraph>The median age was 55 years (range: 31 to 80 years); 87% of patients were younger than 65 years. The majority of patients were female (99%) and White (76%). At study entry, all patients had an ECOG performance status of 0 (29%) or 1 (71%). Seventy-six percent had visceral disease, 42% had hepatic metastases, 56% had lung/pleura metastases, and 2% had brain metastases. Twelve patients (11%) had Stage IV disease at the time of initial diagnosis.</paragraph>
                              <paragraph>The median number of prior systemic therapies received in the metastatic setting was 3 (range: 2 to 10). Prior chemotherapies in the metastatic setting included carboplatin or cisplatin (69%), gemcitabine (55%), paclitaxel or docetaxel (53%), capecitabine (51%), eribulin (45%), doxorubicin (24%), vinorelbine (16%), cyclophosphamide (19%), and ixabepilone (8%).</paragraph>
                              <paragraph>Overall, 98% of patients had received prior taxanes and 86% had received prior anthracyclines either in the (neo)adjuvant or metastatic setting.</paragraph>
                              <paragraph>Table 11 summarizes the efficacy results.</paragraph>
                              <table width="60%">
                                 <caption>Table 11: Efficacy results for patients with mTNBC in IMMU-132-01</caption>
                                 <col width="60%" align="left" valign="middle"/>
                                 <col width="40%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">TRODELVY<br/>(N=108)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="2">CI: confidence interval</td>
                                    </tr>
                                    <tr>
                                       <td colspan="2">+: denotes ongoing</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Overall Response Rate <footnote ID="t12f1">investigator assessment</footnote>
                                          </content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  ORR (95% CI)</td>
                                       <td styleCode="Rrule">33.3% (24.6, 43.1)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">    Complete response</td>
                                       <td styleCode="Rrule">2.8%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">    Partial response</td>
                                       <td styleCode="Rrule">30.6%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Response duration <footnoteRef IDREF="t12f1"/>
                                          </content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Number of responders</td>
                                       <td styleCode="Rrule">36</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Median, Months (95% CI)</td>
                                       <td styleCode="Rrule">7.7 (4.9, 10.8)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Range, Months</td>
                                       <td styleCode="Rrule">1.9+, 30.4+</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  % with duration ≥ 6 months</td>
                                       <td styleCode="Rrule">55.6%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">  % with duration ≥ 12 months</td>
                                       <td styleCode="Rrule">16.7%</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="82e0172d-aad3-407d-80f5-c408fa28aa15"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer</title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="e8432a1a-ce7b-40fa-b545-ea9e1e15bd94"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">TROPiCS-02 Study</content>
                              </paragraph>
                              <paragraph>The efficacy of TRODELVY was evaluated in a multicenter, open label, randomized study (TROPiCS-02; NCT03901339) conducted in 543 patients with unresectable locally advanced or metastatic HR-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer whose disease has progressed after the following in any setting: a CDK 4/6 inhibitor, endocrine therapy, and a taxane; patients received at least two prior chemotherapies in the metastatic setting (one of which could be in the neoadjuvant or adjuvant setting if recurrence occurred within 12 months).</paragraph>
                              <paragraph>Patients were randomized (1:1) to receive TRODELVY 10 mg/kg as an intravenous infusion on Days 1 and 8 of a 21 day cycle (n=272) or single agent chemotherapy (n=271). Single agent chemotherapy was determined by the investigator before randomization from one of the following choices: eribulin (n=130), vinorelbine (n=63), gemcitabine (n=56), or capecitabine (n=22). Randomization was stratified by the following factors: prior chemotherapy regimens for metastatic disease (2 vs. 3–4), visceral metastasis (Yes or No), and endocrine therapy in the metastatic setting for at least 6 months (Yes or No).</paragraph>
                              <paragraph>Patients were treated until disease progression or unacceptable toxicity. Administration of TRODELVY was permitted beyond RECIST-defined disease progression if the patient was clinically stable and considered by the investigator to be deriving clinical benefit. The primary efficacy outcome measure was PFS as determined by BICR per RECIST v1.1. Additional efficacy measures included OS, ORR by BICR, and DOR by BICR.</paragraph>
                              <paragraph>The median age of patients in the study population was 56 years (range: 27–86 years), 26% of patients were 65 years or over. The majority of patients were female (99%); 67% were White, 4% were Black and 3% were Asian, and 26% were of unknown race. Patients received a median of 7 (range: 3 to 17) prior systemic regimens in any setting and 3 (range: 0 to 8) prior systemic chemotherapy regimens in the metastatic setting. Approximately 42% of patients had 2 prior chemotherapy regimens for treatment of metastatic disease compared to 58% of patients who had 3 to 4 prior chemotherapy regimens and all patients had an ECOG performance status of 0 (45%) or 1 (55%). Ninety-five percent of patients had visceral metastases. Most patients received endocrine therapy in the metastatic setting for ≥ 6 months (86%). </paragraph>
                              <paragraph>TRODELVY demonstrated a statistically significant improvement in PFS and OS versus single agent chemotherapy. </paragraph>
                              <paragraph>The efficacy results are summarized in Table 12 and Figure 3 and Figure 4.</paragraph>
                              <table width="85%">
                                 <caption>Table 12: Efficacy Results from TROPiCS-02</caption>
                                 <col width="34%" align="left" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule" colspan="2">All Randomized Patients</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">TRODELVY<br/>n=272</th>
                                       <th styleCode="Rrule">Single Agent Chemotherapy<br/>n=271</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Progression-Free Survival by BICR<footnote>PFS is defined as the time from the date of randomization to the date of the first radiological disease progression or death due to any cause, whichever comes first.</footnote>
                                          </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Median PFS in months<br/> (95% CI)</td>
                                       <td styleCode="Rrule">5.5<br/>(4.2, 7.0)</td>
                                       <td styleCode="Rrule">4.0<br/>(3.1, 4.4)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hazard ratio (95% CI)</td>
                                       <td styleCode="Rrule" colspan="2">0.661 (0.529, 0.826)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">p-value<footnote ID="t13f2">Stratified log-rank test adjusted for stratification factors: prior chemotherapy regimens for metastatic disease (2 vs. 3–4), visceral metastasis (Y/N), and endocrine therapy in the metastatic setting for at least 6 months (Yes or No).<br/>BICR = Blinded Independent Central Review; CI = Confidence Interval</footnote>
                                       </td>
                                       <td styleCode="Rrule" colspan="2">0.0003</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Overall Survival<footnote ID="t9f3">Second interim OS analysis (conducted when 390 OS events were observed)</footnote>
                                          </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Median OS in months<br/> (95% CI)</td>
                                       <td styleCode="Rrule">14.4<br/>(13.0, 15.7)</td>
                                       <td styleCode="Rrule">11.2<br/>(10.1, 12.7)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hazard ratio (95% CI)</td>
                                       <td styleCode="Rrule" colspan="2">0.789 (0.646, 0.964)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">p-value<footnoteRef IDREF="t13f2"/>
                                       </td>
                                       <td styleCode="Rrule" colspan="2">0.0200</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Objective Response Rate by BICR</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Response Rate, % (95% CI)</td>
                                       <td styleCode="Rrule">21.0 (16.3, 26.3)</td>
                                       <td styleCode="Rrule">14.0 (10.1, 18.7)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Odds ratio (95% CI)</td>
                                       <td styleCode="Rrule" colspan="2">1.625 (1.034, 2.555)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">p-value</td>
                                       <td styleCode="Rrule" colspan="2">0.0348</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="3">
                                          <content styleCode="bold">Duration of Response (DOR) by BICR</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Median DOR in months<br/>(95% CI)</td>
                                       <td styleCode="Rrule">8.1<br/> (6.7, 9.1)</td>
                                       <td styleCode="Rrule">5.6<br/> (3.8, 7.9)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="bold">Figure 3: Kaplan-Meier Plot of PFS by BICR in TROPiCS-02</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM4"/>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure 4: Kaplan-Meier Plot of OS in TROPiCS-02</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM5"/>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                           <component>
                              <observationMedia ID="MM4">
                                 <text>Figure 3</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="trodelvy-04.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM5">
                                 <text>Figure 4</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="trodelvy-05.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S15">
               <id root="55728f6d-620a-4c57-925d-8547d69cc993"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph ID="ref1">1. 	"OSHA Hazardous Drugs." OSHA. <content styleCode="italics">http://www.osha.gov/SLTC/hazardousdrugs/index.html</content>.</paragraph>
               </text>
               <effectiveTime value="20250331"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="a41e474d-ece7-4f4d-ba2d-05c602ce79ad"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>TRODELVY (sacituzumab govitecan-hziy) for injection is a sterile, off-white to yellowish lyophilized powder in a single-dose vial. Each TRODELVY vial is individually boxed in a carton:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>NDC 55135-132-01 contains one 180 mg vial</item>
                  </list>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <section>
                     <id root="bd3b293a-9caf-49e8-bfa1-433290aee327"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of reconstitution. Do not freeze.</paragraph>
                        <paragraph>TRODELVY is a hazardous drug. Follow applicable special handling and disposal procedures<sup>1</sup>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="46d2626c-501a-4c76-bcec-5febf1371fc0"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="italics">Advise the patient to read the FDA-approved patient labeling (Patient Information)</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <section>
                     <id root="afbcb574-4da4-4853-bb62-d9739c56da4d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Neutropenia</content>
                        </paragraph>
                        <paragraph>Advise patients of the risk of neutropenia. Instruct patients to immediately contact their healthcare provider if they experience fever, chills, or other signs of infection <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f904069e-f639-4805-a422-cead702ffa64"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Diarrhea</content>
                        </paragraph>
                        <paragraph>Advise patients of the risk of diarrhea. Instruct patients to immediately contact their healthcare provider if they experience diarrhea for the first time during treatment; black or bloody stools; symptoms of dehydration such as lightheadedness, dizziness, or faintness; inability to take fluids by mouth due to nausea or vomiting; or inability to get diarrhea under control within 24 hours <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0f18efaa-97a6-41fb-b9ab-9a4fc927a16d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity and Infusion-Related Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients of the risk of serious infusion reactions and anaphylaxis. Instruct patients to immediately contact their healthcare provider if they experience facial, lip, tongue, or throat swelling, urticaria, difficulty breathing, lightheadedness, dizziness, chills, rigors, wheezing, pruritus, flushing, rash, hypotension, or fever that occur during or within 24 hours following the infusion <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="809e328f-e6c4-4788-99c7-2b1b5b330851"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Nausea/Vomiting</content>
                        </paragraph>
                        <paragraph>Advise patients of the risk of nausea and vomiting. Premedication according to established guidelines with a two or three drug regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) is also recommended. Additional antiemetics, sedatives, and other supportive measures may also be employed as clinically indicated. All patients should receive take-home medications for preventing and treating delayed nausea and vomiting, with clear instructions. Instruct patients to immediately contact their healthcare provider if they experience uncontrolled nausea or vomiting <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="a39c7416-d328-4d5a-8a9f-6721a08d2a03"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryo-Fetal Toxicity</content>
                        </paragraph>
                        <paragraph>Advise female patients to contact their healthcare provider if they are pregnant or become pregnant. Inform female patients of the risk to a fetus and potential loss of the pregnancy <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="17160964-07d6-48fd-9a0e-bfce4311cb1d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>Advise female patients of reproductive potential to use effective contraception during treatment and for 6 months after the last dose of TRODELVY <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of TRODELVY <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f9d9ec17-ffdd-464a-ad5f-c55a10aa696a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise women not to breastfeed during treatment and for 1 month after the last dose of TRODELVY <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d4254ccf-a19a-474b-9b30-652d5cae4543"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential that TRODELVY may impair fertility <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="dd021635-3c1d-46b2-8f32-dadf51449371"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>Gilead Sciences, Inc.<br/>333 Lakeside Dr.<br/>Foster City, CA 94404, USA<br/>
                     <br/>U.S. License No. 2258</paragraph>
               </text>
               <effectiveTime value="20250331"/>
            </section>
         </component>
         <component>
            <section>
               <id root="61e50a58-999d-4685-ac25-5355d1cdcfb8"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="2%" align="left" valign="top"/>
                     <col width="54%" align="left" valign="top"/>
                     <col width="44%" align="left" valign="top"/>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="2">The Patient Information has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right">Revised: 03/2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3" align="center">
                              <content styleCode="bold">Patient Information</content>
                              <br/>TRODELVY<sup>®</sup> (troh-DELL-vee)<br/>(sacituzumab govitecan-hziy)<br/>for injection, for intravenous use</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <paragraph ID="whatis">
                                 <content styleCode="bold">What is the most important information I should know about TRODELVY?<br/>TRODELVY can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Low white blood cell count (neutropenia).</content> Low white blood cell counts are common with TRODELVY and can sometimes be severe and lead to infections that can be life-threatening or cause death as early as the first cycle of treatment. Your healthcare provider should check your blood cell counts during treatment with TRODELVY and may give a medicine to help prevent low blood cell count starting in the first cycle of treatment if you have an increased risk for developing low white blood cell count with a fever (febrile neutropenia). If your white blood cell count is too low, your healthcare provider may need to delay treatment or lower your dose of TRODELVY, give you a medicine to treat low blood cell count, or in some cases may permanently stop TRODELVY. Your healthcare provider may need to give you antibiotic medicines if you develop fever while your white blood cell count is low. <br/>
                                    <content styleCode="bold">Call your healthcare provider right away if you develop any of the following signs of infection during treatment with TRODELVY</content>:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>fever</item>
                                 <item>chills</item>
                                 <item>cough</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>shortness of breath</item>
                                 <item>burning or pain when you urinate</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Severe diarrhea.</content> Diarrhea is common with TRODELVY and can also be severe. Severe diarrhea can lead to loss of too much body fluid (dehydration) and kidney problems. Your healthcare provider should monitor you for diarrhea and give you medicine as needed to help control your diarrhea. If you lose too much body fluid, your healthcare provider may need to give you fluids and electrolytes to replace body salts. If you develop diarrhea during treatment with TRODELVY, your healthcare provider should check to see if diarrhea may be caused by an infection. Your healthcare provider may decrease your dose, delay treatment, or permanently stop TRODELVY if your diarrhea is severe and cannot be controlled with anti-diarrheal medicines.<br/>
                                    <content styleCode="bold">Call your healthcare provider right away:</content>
                                    <list listType="unordered" styleCode="circle">
                                       <item>the first time that you get diarrhea during treatment with TRODELVY</item>
                                       <item>if you have black or bloody stools</item>
                                       <item>if you have symptoms of losing too much body fluid and body salts, such as lightheadedness, dizziness, or faintness</item>
                                       <item>if you are unable to take fluids by mouth due to nausea or vomiting</item>
                                       <item>if you are not able to get your diarrhea under control within 24 hours</item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">What is TRODELVY?</content>
                              <br/>TRODELVY is a prescription medicine used to treat adults with:<list listType="unordered" styleCode="disc">
                                 <item>a type of breast cancer called triple-negative breast cancer (TNBC), which is estrogen and progesterone hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative. TRODELVY may be used:<list listType="unordered" styleCode="circle">
                                       <item>when your breast cancer has spread to other parts of the body (metastatic) or cannot be removed by surgery, <br/>
                                          <content styleCode="bold">and</content>
                                       </item>
                                       <item>if you previously received two or more prior treatments, including at least one treatment for metastatic disease. </item>
                                    </list>
                                 </item>
                                 <item>a type of breast cancer that is HR-positive and HER2-negative. TRODELVY may be used:<list listType="unordered" styleCode="circle">
                                       <item>when your breast cancer has spread to other parts of the body or cannot be removed by surgery,<br/>
                                          <content styleCode="bold">and</content>
                                          <br/>if you previously received endocrine therapy and at least two additional treatments for metastatic disease.</item>
                                    </list>
                                 </item>
                              </list>									It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems.<br/>It is not known if TRODELVY is safe and effective in children.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">Do not receive TRODELVY if you have had a severe allergic reaction to TRODELVY.</content> Ask your healthcare provider if you are not sure.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">Before receiving TRODELVY, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>have been told that you carry a gene for uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28. People who carry this gene have an increased risk of getting side effects with TRODELVY, especially low white blood cell counts, a fever while your white blood cell count is low, and low red blood cell counts. <content styleCode="bold">See "<linkHtml href="#whatis">What is the most important information I should know about TRODELVY?</linkHtml>"</content>
                                 </item>
                                 <item>have liver problems.</item>
                                 <item>are pregnant or plan to become pregnant. TRODELVY can harm your unborn baby. Your healthcare provider should check to see if you are pregnant before you start receiving TRODELVY.<list listType="unordered" styleCode="circle">
                                       <item>Females who can become pregnant should use effective birth control during treatment and for 6 months after your last dose of TRODELVY. Talk to your healthcare provider about birth control choices that may be right for you during this time. Tell your healthcare provider right away if you become pregnant during treatment with TRODELVY.</item>
                                       <item>Males with a female partner who can become pregnant should use effective birth control during treatment and for 3 months after your last dose of TRODELVY.</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if TRODELVY passes into your breastmilk and can harm your baby. Do not breastfeed during treatment and for 1 month after your last dose of TRODELVY.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the way TRODELVY works.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">How will I receive TRODELVY?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Your healthcare provider will give you TRODELVY into your vein through an intravenous (IV) line.</item>
                                 <item>TRODELVY is given 1 time each week, on Day 1 and on Day 8 of a 21-day treatment cycle. </item>
                                 <item>You will receive the first dose of TRODELVY over 3 hours. If you tolerate the first dose well, future doses may be given over 1 to 2 hours.</item>
                                 <item>Before each dose of TRODELVY, you will receive medicines to help prevent infusion-related reactions, and nausea and vomiting.</item>
                                 <item>You will be monitored for side effects during and for at least 30 minutes after you receive each infusion of TRODELVY.</item>
                                 <item>Your healthcare provider may slow down or temporarily stop your infusion of TRODELVY if you have an infusion-related reaction, or permanently stop TRODELVY if you have a life-threatening infusion-related reaction.</item>
                                 <item>Your healthcare provider will decide how long you will continue to receive TRODELVY.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">What are the possible side effects of TRODELVY?</content>
                              <br/>TRODELVY can cause serious side effects, including:<list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">See "<linkHtml href="#whatis">What is the most important information I should know about TRODELVY?</linkHtml>"</content>
                                 </item>
                                 <item>
                                    <content ID="allergic">
                                       <content styleCode="bold">Allergic and infusion-related reactions</content>. TRODELVY can cause serious or life-threatening allergic and infusion-related reactions. Tell your healthcare provider or nurse right away if you get any of the following symptoms of an allergic or infusion-related reaction during your infusion of TRODELVY or within 24 hours after you receive a dose of TRODELVY:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>swelling of your face, lips, tongue, or throat</item>
                                 <item>hives</item>
                                 <item>skin rash, itching, or flushing of your skin</item>
                                 <item>fever</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>difficulty breathing or wheezing</item>
                                 <item>lightheadedness, dizziness, feeling faint or pass out </item>
                                 <item>chills or shaking chills (rigors)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Nausea and vomiting</content>. Nausea and vomiting are common with TRODELVY and can sometimes be severe. Before each dose of TRODELVY, you will receive medicines to help prevent nausea and vomiting. You should be given medicines to take home with you, along with instructions about how to take them to help prevent and treat any nausea and vomiting after you receive TRODELVY. Call your healthcare provider right away if you have nausea or vomiting that is not controlled with the medicines prescribed for you. Your healthcare provider may decide to decrease your dose, delay treatment, or permanently stop TRODELVY if your nausea and vomiting is severe and cannot be controlled with anti-nausea medicines.</item>
                              </list>
                              <content styleCode="bold">The most common side effects of TRODELVY include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="disc">
                                 <item>decreased white blood cell (leukocyte and lymphocyte) and red blood cell counts</item>
                                 <item>feeling tired or weak</item>
                                 <item>hair loss</item>
                                 <item>constipation</item>
                                 <item>increased sugar levels in the blood</item>
                                 <item>decreased protein levels (albumin) in the blood</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>decreased appetite</item>
                                 <item>changes in kidney function test</item>
                                 <item>increased levels of enzyme called alkaline phosphatase in the blood (test for liver or bone problems)</item>
                                 <item>decreased levels of magnesium, potassium, and sodium in the blood</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">TRODELVY may cause fertility problems in females, which could affect your ability to have a baby. Talk to your healthcare provider if fertility is a concern for you.<br/>These are not all of the possible side effects of TRODELVY.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">General information about the safe and effective use of TRODELVY.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about TRODELVY that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">What are the ingredients in TRODELVY?<br/>Active ingredient</content>: sacituzumab govitecan-hziy<br/>
                              <content styleCode="bold">Inactive ingredients</content>: 2-(N-morpholino) ethane sulfonic acid (MES), polysorbate 80 and trehalose<br/>Manufactured by: Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, CA 94404, USA<br/>U.S. License No. 2258<br/>761115-GS-010<br/>For more information about TRODELVY, go to www.TRODELVY.com or call 1-888-983-4668.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250331"/>
            </section>
         </component>
         <component>
            <section ID="s70">
               <id root="668a3767-63b9-4ca6-b24a-69383d27d969"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 180 mg Vial Label</title>
               <text>
                  <paragraph>NDC 55135-132-01</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>TRODELVY<sup>®</sup>
                     <br/>						sacituzumab govitecan-hziy<br/>						For injection</paragraph>
                  <paragraph>180 mg per vial</paragraph>
                  <paragraph>For intravenous infusion only</paragraph>
                  <paragraph>Warning: Hazardous Drug</paragraph>
                  <paragraph>Single-dose vial<br/>Discard unused portion</paragraph>
                  <paragraph>90370103</paragraph>
                  <renderMultiMedia ID="f02" referencedObject="mm02"/>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <observationMedia ID="mm02">
                     <text>PRINCIPAL DISPLAY PANEL - 180 mg Vial Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="trodelvy-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s69">
               <id root="9c744980-4fe8-4b42-a23e-04d53accabe8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 180 mg Vial Box</title>
               <text>
                  <paragraph>NDC 55135-132-01</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>TRODELVY<sup>®</sup>
                     <br/>						sacituzumab govitecan-hziy<br/>						For injection</paragraph>
                  <paragraph>180 mg per vial</paragraph>
                  <paragraph>For intravenous infusion only</paragraph>
                  <paragraph>Warning: Hazardous Drug</paragraph>
                  <paragraph>Reconstitute and dilute<br/>immediately prior to use</paragraph>
                  <paragraph>Single-dose vial<br/>Discard unused portion</paragraph>
                  <paragraph>1 Vial</paragraph>
                  <renderMultiMedia ID="f03" referencedObject="mm03"/>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <observationMedia ID="mm03">
                     <text>PRINCIPAL DISPLAY PANEL - 180 mg Vial Box</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="trodelvy-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>